Article
Florida Cancer Specialists Researcher Co-Authored SABCS Breast Cancer Study
A member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS) served as co-author of a study presented at San Antonio Breast Cancer Symposium.
Fort Myers, Florida — Medical oncologist James Reeves, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), served as co-author of a study shared in a poster presentation at the San Antonio Breast Cancer Symposium, which was held December 7-12, 2021.
Entitled, “Correlation Between Presence of Circulating Tumor DNA and Response to Neoadjuvant Niraparib in HER2-Negative, BRCA-Mutated Breast Cancer,” the study's analysis indicates a correlation between the TP53 gene and tumor volume following treatment with niraparib over time.
“Mutations in TP53 occur in 30% to 35% of invasive primary breast cancer cases and may be an effective biomarker. Nuraparib, a poly(ADP-ribose) polymerase (PARP)-1/2 inhibitor, provides a new, effective treatment option for BRCA 1/2-mutated early-stage breast cancer after chemotherapy,” said Dr Reeves and fellow researchers.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
